Seventh and Eighth O3b mPOWER Satellites to Start Delivering Connectivity Services
SES announced today that the latest pair of O3b mPOWER satellites launched in December 2024 is now ready to offer services across the globe.
Featuring redesigned payload power modules, the seventh and eighth O3b mPOWER satellites are bolstering the capabilities of SES’s second-generation medium earth orbit (MEO) system, supporting the delivery of high throughput and predictable low latency services at scale. To date, SES has launched eight out of 13 O3b mPOWER high-throughput and low-latency satellites. The next O3b mPOWER launch is scheduled for summer 2025.
SES has also expanded its strategically located satellite ground stations, and now has 12 operational O3b mPOWER gateways located in South Africa, Peru, Brazil, Portugal, Australia, Greece, the U.S., Chile, the United Arab Emirates and Senegal. Five out of these are co-located and operated by Microsoft’s Azure data centres.
“Our O3b mPOWER services are in high demand and we were eagerly awaiting the additional satellites to strengthen our MEO network,” said Adel Al-Saleh, CEO of SES. “As we continue to deploy additional O3b mPOWER satellites, we are bringing substantially more capacity and improved network efficiency, resulting in a threefold increase in available capacity by 2027 to better serve our mobility, government, enterprise and cloud customers.”
SES started offering O3b mPOWER services worldwide since April 2024 and has been delivering high-performance network services to customer sites across Asia-Pacific, Africa, the Middle East and the Americas in multiple market segments. The system’s exceptional flexibility means it can provide services ranging from tens of Mbps to multiple gigabits per second of capacity to any site.
Follow us on:
Twitter | Facebook | YouTube | LinkedIn | Instagram
Read our Blogs >
Visit the Media Gallery >
About SES
SES has a bold vision to deliver amazing experiences everywhere on Earth by distributing the highest quality video content and providing seamless data connectivity services around the world. As a provider of global content and connectivity solutions, SES owns and operates a geosynchronous orbit fleet and medium earth orbit (GEO-MEO) constellation of satellites, offering a combination of global coverage and high performance services. By using its intelligent, cloud-enabled network, SES delivers high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners around the world. The company is headquartered in Luxembourg and listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250602091667/en/
Contacts
For further information please contact:
Suzanne Ong
Communications
Tel. +352 710 725 500
suzanne.ong@ses.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Special Seminar Paves the Way for European Dairy Brands to Enter China ’ s Special Food Market Under New Rules5.6.2025 05:50:00 EEST | Press release
CCIC Europe Food Test Co., Ltd. (CCIC EFT) is stepping up efforts to help more European companies access China’s infant formula market. On June 25–26, CCIC EFT will host a targeted seminar in Wageningen, the Netherlands, focused on regulatory updates and market access for producers of infant formula, older infant and toddler milk-based formula, and food for special medical purposes (FSMP). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250604444992/en/ CCIC Europe Food Test Co., Ltd. (CCIC EFT) and Technology Innovation Center of Special Food, State Administration of Market Regulation (TISF, SAMR) in the Netherlands. Co-organized with the Technology Innovation Center of Special Food, State Administration of Market Regulation (TISF, SAMR), the seminar is designed for professionals familiar with Chinese regulations and seeking the latest updates on standards, product registration, and market trends. Attendees will benefit from
Belkin Unveils New Gaming Portfolio Featuring Power-Packed Charging Accessories and Gaming Essentials5.6.2025 02:00:00 EEST | Press release
Belkin, a leading consumer electronics brand for over 40 years, today announced its entry into the gaming accessories space with the launch of a new lineup designed to be compatible with the highly anticipated Nintendo Switch 2. Built on decades of experience in power, connectivity and device protection, and released under Belkin’s innovation-focused Future Ventures category, this marks the company’s first collection of products tailored specifically for the gaming community. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250604528148/en/ Belkin’s lineup of Nintendo Switch 2 accessories Belkin is “Leveling up your play” – bringing a new level of reliability to the gaming ecosystem that differentiates through premium materials, timeless design, and in-house engineering. The new range includes elevated accessories designed to enhance the Nintendo Switch 2 experience, featuring on-the-go charging solutions, audio gear, robust s
Biocytogen and Nanjing Chia Tai Tianqing Announce IND Approval in China for Co-Developed Anti-IGF-1R Antibody NTB003 (BCG009)5.6.2025 02:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) and Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. (“NJCTTQ”) announced that NTB003 (formerly BCG009), a co-developed injectable drug candidate, has received the Investigational New Drug (IND) approval from the National Medical Products Administration (NMPA). The approved indication is Thyroid Eye Disease (TED). About NTB003 Injection NTB003 is a second-generation fully human anti-IGF-1R monoclonal antibody co-developed by Biocytogen and Nanjing Chia Tai Tianqing. Antibody discovery and optimization were completed by Biocytogen using its proprietary RenMab™ fully human antibody discovery platform, while Nanjing Chia Tai Tianqing was responsible for CMC process development, GLP-compliant toxicology studies, and IND application. Compared with first-generation approved anti-IGF-1R therapeutics, NTB003 demonstrates enhanced molecular affinity, improved druggability, and an extended half-life. In vitro studies ha
New Potential Treatment Strategy for Brain Metastases and Leptomeningeal Disease: HER3-DXd Shows Promising Results in the Phase II TUXEDO-3 Study for Patients With Limited Therapeutic Options4.6.2025 21:19:00 EEST | Press release
Leading international medical research company, MEDSIR announced today the positive results of the TUXEDO-3 trial at the American Society of Clinical Oncology (ASCO) Annual Meeting 2025. This phase II study funded by Daiichi Sankyo and Merck, known as MSD outside of the United States and Canada, evaluates the efficacy and safety of patritumab deruxtecan (HER3-DXd) in patients with active brain metastases and leptomeningeal disease, serious complications associated with advanced stages of the cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250604087994/en/ Dr. Matthias Preusser during Oral Presentation of TUXEDO-3 at ASCO 2025 The study was carried out to evaluate HER3-DXd in patients with metastatic breast cancer (mBC) and advanced non-small cell lung cancer (aNSCLC) with active brain metastases, and patients with leptomeningeal disease from solid tumors. This is an antibody-drug conjugate to target HER3, a protein re
QPS Celebrates 30 th Anniversary4.6.2025 19:00:00 EEST | Press release
QPS Holdings, LLC (QPS), an award-winning contract research organization (CRO) focused on bioanalytics and clinical trials, is celebrating its 30-year anniversary in 2025. Founded by Dr. Benjamin Chien in 1995 to provide high-quality bioanalytical liquid chromatography with tandem mass spectrometry (LC-MS/MS) contract services, QPS is now recognized as a global leader in contract research. Over the past 30 years, the company has grown from a single office in Delaware, USA to a widely respected, global, full-service CRO with 8 locations spread across the US, EU, Asia, India and Australia, a clinical trial network of over 700 sites and an increased focus on leveraging the power of AI to accelerate clinical trials. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250604778675/en/ Dr. Benjamin Chien founder and CEO of QPS Holdings, LLC. Over the years, QPS has grown from a small molecule bioanalysis shop of three people to a globa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom